Newron Pharmaceuticals S.p.A.

BATS-CHIXE:NWRNZ Stock Report

Market Cap: CHF 314.2m

Newron Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NWRNZ?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders960,0004.81%
Institutions1,224,1866.13%
General Public17,776,80889.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 20 shareholders own 10.94% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4.81%
Tobias Scherer
960,000CHF 15.1m0%no data
3.1%
UBS Asset Management AG
618,150CHF 9.7m3.07%no data
0.62%
ZKB Asset Management
123,154CHF 1.9m0%no data
0.48%
Zürcher Kantonalbank
96,067CHF 1.5m0%0.01%
0.45%
Baader Bank Aktiengesellschaft
90,595CHF 1.4m0%0.12%
0.38%
Heights Capital Management, Inc.
75,008CHF 1.2m0%-1.21%
0.3%
BlackRock, Inc.
60,188CHF 947.4k8.13%no data
0.18%
Aramea Asset Management AG
35,000CHF 550.9k0%0.1%
0.11%
BCV Asset Management
21,000CHF 330.6k0%0.01%
0.1%
Deutsche Asset & Wealth Management
20,000CHF 314.8k0%no data
0.09%
Wyss & Partner AG
18,000CHF 283.3k0%0.76%
0.069%
Pictet Asset Management Limited
13,763CHF 216.6k0%no data
0.058%
Knoesel & Ronge Vermögensverwaltung GmbH & Co. Kg
11,500CHF 181.0k0%0.33%
0.055%
Lombard Odier Asset Management (Switzerland) SA
10,990CHF 173.0k0%no data
0.042%
Baloise Asset Management
8,429CHF 132.7k0%0.01%
0.04%
amandea Vermögensverwaltung AG
8,000CHF 125.9k0%0.37%
0.04%
Spinoza Capital Gmbh
8,000CHF 125.9k0%1.51%
0.012%
State Street Global Advisors, Inc.
2,463CHF 38.8k0%no data
0.012%
American Century Investment Management Inc
2,402CHF 37.8k0%no data
0.0074%
LLB Asset Management AG
1,477CHF 23.2k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/19 20:56
End of Day Share Price 2025/11/19 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Newron Pharmaceuticals S.p.A. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas MeyerBaader Helvea Equity Research
Jyoti PrakashEdison Investment Research
Lucy CodringtonJefferies LLC